ITCI — Intra-Cellular Therapies Share News
0.000.00%
Last trade - 00:00- $14.04bn
- $13.04bn
- $680.85m
Intra-Cellular's drug for depression meets main goal in late-stage trial
Brief: Intra-Cellular Therapies Announces Positive Topline Results In Second Phase 3 Trial Testing Lumateperone As Adjunctive Depression Therapy
U.S. RESEARCH ROUNDUP-Biontech, Honeywell International, Klaviyo
Intra-Cellular Therapies Inc reports results for the quarter ended in March - Earnings Summary
Brief: Intra-Cellular Therapies Q1 Net Income USD -15.2 Million
Intra-Cellular Therapies Inc expected to post a loss of 32 cents a share - Earnings Preview
Intra-Cellular Therapies Inc expected to post a loss of 32 cents a share - Earnings Preview
Intra-Cellular Therapies slips on $500 mln stock offering
Brief: Intra-Cellular Therapies Prices Public Offering Of Common Stock
U.S. RESEARCH ROUNDUP-3M, J&J, Nuvalent
Brief: Intra-Cellular Therapies Files For Mixed Shelf Offering, Size Not Disclosed - SEC Filing
Brief: Intra-Cellular Therapies Inc Sees Preliminary Q1 Caplyta Net Product Sales Of About $144.8 Million
U.S. STOCKS ON THE MOVE-US Health Insurers, Palisade Bio, Dynatronics
Intra-Cellular Therapies up as depression drug meets main goal of late-stage study
Brief: Intra-Cellular Therapies- Filed Lawsuits On March 27 & March 28, Against Generic Drug Makers Who Notified Co Of ANDA Filings For Caplyta
Intra-Cellular Therapies Inc reports results for the quarter ended in December - Earnings Summary
Brief: Intra-Cellular Therapies Q4 Net Income USD -139.7 Million
Intra-Cellular Therapies Inc expected to post a loss of 44 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-American Water Works Company, Home Depot, Lowe's